Table 1. Baseline characteristics of patients stratified using a cutoff value of 2 for CHADS2 and CHA2DS2-VASc scores.
| Variable | CHADS2 score | CHA2DS2-VASc score | ||||
| <2 (n = 1,805) | ≥2 (n = 1,378) | P value | <2 (n = 1,242) | ≥2 (n = 1,941) | P value | |
| Age, years | 58.3±12.1 | 71.5±12.1 | <0.001 | 53.4±9.4 | 70.9±11.6 | <0.001 |
| Age 65–75 years | 439 (24.3) | 313 (22.7) | 0.16 | 122 (9.8) | 630 (32.5) | <0.001 |
| Age ≥75 years | 129 (7.1) | 679 (49.3) | <0.001 | 0 (0) | 808 (41.6) | <0.001 |
| Male | 1,546 (85.7) | 937 (68.0) | <0.001 | 1,196 (96.3) | 1,287 (66.3) | <0.001 |
| Medical History | ||||||
| Current smoker | 946 (52.4) | 367 (26.6) | <0.001 | 774 (62.8) | 539 (27.6) | <0.001 |
| Hypertension | 734 (41.2) | 1,282 (93.5) | <0.001 | 421 (33.9) | 1,595 (82.2) | <0.001 |
| Diabetes | 208 (11.6) | 930 (67.7) | <0.001 | 122 (9.8) | 1016 (52.3) | <0.001 |
| Hyperlipidemia | 599 (33.6) | 636 (46.4) | <0.001 | 402 (32.8) | 833 (42.9) | <0.001 |
| Congestive heart failure | 12 (0.7) | 160 (11.6) | <0.001 | 3 (0.2) | 169 (8.7) | <0.001 |
| Previous CAD | 275 (15.2) | 507 (36.8) | <0.001 | 115 (9.3) | 667 (34.3) | <0.001 |
| Previous myocardial infarction | 107 (21.3) | 208 (31.9) | <0.001 | 25 (2.0) | 290 (14.9) | <0.001 |
| Previous stroke/TIA | 0 (0) | 287 (20.8) | <0.001 | 0 (0) | 287 (14.8) | <0.001 |
| Peripheral arterial disease | 13 (0.7) | 58 (4.2) | <0.001 | 2 (0.2) | 69 (3.6) | <0.001 |
| Vascular disease§ | 119 (6.6) | 259 (18.8) | <0.001 | 27 (2.2) | 340 (17.5) | <0.001 |
| History of atrial fibrillation | 30 (1.7) | 73 (5.3) | <0.001 | 8 (0.6) | 95 (4.9) | <0.001 |
| Chronic kidney disease | 314 (17.4) | 609 (44.2) | <0.001 | 171 (13.8) | 752 (38.7) | <0.001 |
| COPD | 40 (2.2) | 83 (6.0) | <0.001 | 14 (1.1) | 109 (5.6) | <0.001 |
| Clinical presentation | ||||||
| ST-elevation MI | 1,120 (62.0) | 583 (42.3) | <0.001 | 822 (66.2) | 881 (45.4) | <0.001 |
| Non-ST elevation MI | 361 (20.0) | 489 (35.5) | <0.001 | 222 (17.9) | 628 (32.4) | <0.001 |
| Unstable angina | 324 (18.0) | 306 (22.2) | <0.001 | 198 (15.9) | 432 (22.3) | <0.001 |
| Killip class ≥III at admission | 238 (13.2) | 289 (21.0) | <0.001 | 135 (10.9) | 392 (20.2) | <0.001 |
| CK-MB maximum, median ug/L | 76.8±131.3 | 46.6±81.3 | <0.001 | 83.2±138.2 | 51.5±92.5 | <0.001 |
| LVSD (LVEF<40%) | 171 (9.5) | 220 (16.0) | <0.001 | 102 (8.2) | 289 (14.9) | <0.001 |
| Procedures | ||||||
| Fibrinolysis therapy | 33 (2.5) | 22 (2.6) | 0.89 | 22 (2.3) | 33 (2.7) | 0.68 |
| PCI | 1,588 (88.1) | 1,092 (79.5) | <0.001 | 1,111 (89.6) | 1,569 (81.0) | <0.001 |
| Primary PCI | 1,016 (56.3) | 490 (35.6) | <0.001 | 725 (58.4) | 781 (40.2) | <0.001 |
| Rescue PCI | 29 (2.1) | 12 (1.4) | 0.26 | 21 (2.2) | 20 (1.6) | 0.34 |
| CABG | 49 (2.7) | 57 (4.1) | 0.03 | 26 (2.1) | 80 (4.1) | 0.002 |
| Medication at discharge | ||||||
| Dual antiplatelet therapy | 1,351 (74.8) | 1,034 (75.0) | 0.93 | 923 (74.3) | 1,462 (75.3) | 0.53 |
| ACEi/ARB | 1,157 (64.1) | 848 (61.5) | 0.07 | 769 (61.9) | 1,236 (63.9) | 0.32 |
| β-blockers | 988 (54.7) | 712 (51.7) | 0.05 | 653 (52.6) | 1,047 (53.9) | 0.45 |
| Statin therapy | 1,091 (60.4) | 833 (60.4) | 1.00 | 745 (60.0) | 1,179 (60.7) | 0.67 |
| VKA | 34 (1.9) | 33 (2.4) | 0.89 | 26 (2.1) | 41 (2.1) | 0.69 |
Values are presented as number (%) or mean ± SD.
ACEi, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CK-MB, MB fraction of creatine kinase; COPD, chronic obstructive pulmonary disease; LVEF, left ventricular ejection fraction; LVSD, left ventricle systolic dysfunction; MI, myocardial infarction; PCI, percutaneous coronary intervention; TIA, transient ischemic attack; VKA, vitamin K antagonist.
§
Vascular disease defined as previous myocardial infarction or peripheral arterial obstructive disease.